公开(公告)号：US06630165B2

公开(公告)日：2003-10-07

申请号：US10087026

申请日：2002-02-28

申请人： Sylvia L. Seroff ,  Noymi V. Yam ,  Atul D. Ayer ,  Padmanabh P. Bhatt ,  Michael A. Desjardin ,  Andrew C. Lam ,  David E. Edgren ,  Phillip R. Nixon

发明人： Sylvia L. Seroff ,  Noymi V. Yam ,  Atul D. Ayer ,  Padmanabh P. Bhatt ,  Michael A. Desjardin ,  Andrew C. Lam ,  David E. Edgren ,  Phillip R. Nixon

IPC分类号： A61K924

CPC分类号： A61K31/5375 ,  A61K9/0004

摘要： Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

摘要翻译： 提供了用于提供瑞波西汀持续释放的剂型和方法。 当每天施用一次时，缓释剂型提供治疗有效的平均稳态血浆瑞波西汀浓度。 这种每天一次的给药方案导致每24小时内出现一种峰值血浆瑞波西汀浓度。 此外，血浆瑞波西汀峰浓度发生在剂量给药后的稍后时间，并且呈现比在立即释放剂型中施用瑞波西汀后发生的峰值血浆瑞波西汀浓度更小的量值。

公开(公告)号：US06387403B1

公开(公告)日：2002-05-14

申请号：US09661976

申请日：2000-09-14

申请人： Sylvia L. Seroff ,  Noymi V. Yam ,  Atul D. Ayer ,  Padmanabh P. Bhatt ,  Michael A. Desjardin ,  Andrew C. Lam ,  David E. Edgren ,  Phillip R. Nixon

发明人： Sylvia L. Seroff ,  Noymi V. Yam ,  Atul D. Ayer ,  Padmanabh P. Bhatt ,  Michael A. Desjardin ,  Andrew C. Lam ,  David E. Edgren ,  Phillip R. Nixon

IPC分类号： A61K924

CPC分类号： A61K31/5375 ,  A61K9/0004

摘要： Dosage forms and methods for providing sustained release of reboxetine are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma reboxetine concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma reboxetine concentration occurrence in each 24 hour period. In addition, the peak plasma reboxetine concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma reboxetine concentration that occurs following administration of reboxetine in an immediate-release dosage form.

摘要翻译： 提供了用于提供瑞波西汀持续释放的剂型和方法。 当每天施用一次时，缓释剂型提供治疗有效的平均稳态血浆瑞波西汀浓度。 这种每天一次的给药方案导致每24小时内出现一种峰值血浆瑞波西汀浓度。 此外，血浆瑞波西汀峰浓度发生在剂量给药后的稍后时间，并且呈现比在立即释放剂型中施用瑞波西汀后发生的峰值血浆瑞波西汀浓度更小的量值。